

## SUPPLEMENTAL MATERIAL

### BIOCHEMICAL AND STRUCTURAL STUDIES ON THE M. TUBERCULOSIS O<sup>6</sup>-METHYLGUANINE METHYLTRANSFERASE AND MUTATED VARIANTS

Riccardo Miggiano<sup>1§</sup>, Valentina Casazza<sup>1§</sup>, Silvia Garavaglia<sup>1</sup>, Maria Ciaramella<sup>2</sup>,  
Giuseppe Perugino<sup>2</sup>, Menico Rizzi<sup>1\*</sup> and Franca Rossi<sup>1\*</sup>

#### S-1 SUPPLEMENTAL METHODS

#### S-2 TABLE S1

#### S-3 FIGURE S1

#### S-4 FIGURE S2

#### S-5 FIGURE S3

#### S-6 FIGURE S4

#### S-7 FIGURE S5

#### SUPPLEMENTAL METHODS


*Expression and purification of wild-type MtOGT and point mutants* - The three recombinant proteins *MtOGT*, *MtOGT-T15S* and *MtOGT-R37L* were purified by FPLC (Akta Basic Instrument GE Healthcare) from 1 L of the corresponding auto-induced bacterial culture adopting the following workflow. 50 mL of clarified lysate in buffer A [Tris-HCl 20mM pH 7.8 and a commercial protease inhibitor cocktail (Sigma)] were loaded onto a HiTrapQ pre-packed anion exchange column. The retained proteins were then eluted using a linear 0-0.5 M NaCl gradient. Recombinant protein-containing fractions were dialysed against buffer A, applied onto a MonoQ pre-packed column (GE Healthcare) and protein elution was obtained as above. Recombinant protein-containing fractions from the last anion-exchange chromatography step were pooled, desalted by dialysis against buffer A and loaded onto a HiTrap Heparin disposable column (GE Healthcare). Protein elution was obtained by a linear 0-1.0 M NaCl gradient and the eluted fractions containing the recombinant protein were pooled, concentrated to 1 mg/mL by using 10 kDa NMWCO ultrafiltration device (Vivaspin, Vivascience) and loaded onto a Superdex 200 10/300 size exclusion chromatography column (GE Healthcare) using buffer B [20 mM Tris-HCl pH 7.8, 150 mM NaCl] as the mobile phase. Fractions corresponding to the main peak were concentrated to 5 mg/mL by using a 10 kDa NMWCO Vivaspin device. During the entire procedure the recombinant protein was monitored by standard SDS/PAGE analyses (example given in Supplementary Figure 1) and protein concentration was determined by the Bradford assay (Sigma). If not immediately used, the purified proteins were stored in aliquots at -80 °C.

**Table S1 - Oligonucleotides used in the present work**

<b>MtOGTfwd</b> <sup>(a)</sup>	5'-ATAT <u>CCATGGT</u> TTCACTACCGCACCATCGATAGC-3' ( <i>Nco</i> I)
<b>MtOGTrev</b> <sup>(a)</sup>	5'-AAAG <u>GATCCT</u> CAGTCGAAGAGCGTCAAGTCTG-3' ( <i>Bam</i> HI)
<b>T15S fwd</b> <sup>(b)</sup>	5'-CCCATCGGGCCATTA <b>AGC</b> CTGGCCGGGCATGGC-3' ACC
<b>T15S rev</b>	5'-GCCATGCCCGGCCAGGCTTAATGGCCCGATGGG-3'
<b>R37L fwd</b> <sup>(c)</sup>	5'-CGTATGAGCCAAGC <b>CTC</b> ACACACTGGACACCC-3' CGC
<b>R37L rev</b>	5'-GGGTGTCCAGTGTGTGAGGCTTGGCTCATACG-3'
<b>UP</b> <sup>met (d)</sup>	5'-GGACACTGTACGTTAAGG <b>CG</b> *ATCGAATTAGGATTA-3'
<b>DOWN</b> <sup>(d)</sup>	5'-GGTTAATCCTAATTCGATCGCCTAACGTACAGTGT-3'
<b>A</b> <sup>+</sup> <sup>(e)</sup>	5'- <b>TMR</b> -GCAACAACGTTGCGCAAACCTATTAACCTGGCGAACTACTTA-3'
<b>D</b> <sup>-</sup> <sup>(e)</sup>	5'-TAAGTAGTTCGCCAGTTAATAGTTTGC GCAACGTTGTTGC-3'


<sup>(a)</sup> Restriction sites for the endonucleases indicated in brackets are underlined; <sup>(b)</sup> <sup>(c)</sup> point-mutation in each oligonucleotide appears in bold; <sup>(d)</sup> the methylguanine residue in the UP<sup>met</sup> oligonucleotide is labeled by an asterisk; the ds-DNA<sup>met</sup> probe used in enzyme kinetics analysis has been prepared by annealing **UP**<sup>met</sup> and **DOWN** oligonucleotides; <sup>(e)</sup> “**TMR**” indicates the TAMRA<sup>TM</sup> fluorescent group; the dsDNA probe used in EMSA analysis has been prepared by annealing **A**<sup>+</sup> and **D**<sup>-</sup> oligonucleotides.

**Fig. S1**




**Purification of *MtOGT*, *MtOGT-T15S* and *MtOGT-R37L*** - 4  $\mu$ L of each purified protein (5 mg/mL) were separated using a 15% acrylamide-bisacrylamide gel in SDS-PAGE and visualized by Coomassie brilliant blue staining. The three proteins, independently loaded onto a Superdex 200 10/300 size exclusion chromatography column (GE Healthcare), invariably eluted at  $V_e=17.2$  mL, which corresponds to a MW of 18 kDa, as calculated on the basis of the calibration curve of the column.

Fig. S2



**Example of the determination of the kinetic constants of the reaction catalyzed by the recombinant proteins under study.** **A.** Scheme of the assay with the fluorescent substrate/inhibitor SNAP-Vista Green™ (VG); **B.** Time-course experiments of covalent modification of 5  $\mu\text{M}$  *MtOGT* incubated with VG in the range of 0.1-10  $\mu\text{M}$  (VG concentration appears at the right of each corresponding curve) and taking aliquots at 0, 2, 5, 10, 30, 60 min. Similar sets of measurements were carried out for both the *MtOGT*-T15S and *MtOGT*-R37L mutated proteins (not shown); **C.** Plot of the first-order rate constants for covalent modification of *MtOGT* ( $k_{\text{obs}}$ ) as a function of SNAP-Vista Green™ (VG) concentration. Rate values obtained in the time course experiments were fitted according to equation 1 (see the “*Materials and Methods*” section of the main text).

Fig. S3



**Determination of the DNA dissociation constants of the reaction catalyzed by *MtOGT*, *MtOGT-T15S* and *MtOGT-R37L*** - Plots of the variation of  $K_{VG}$  of *MtOGT* (A), *MtOGT-T15S* (B) and *MtOGT-R37L* (C) as a function of the ds-DNA<sup>met</sup> concentration. Data were fitted according to equation 2 (see the “Materials and Methods” section of the main text) that allowed the calculation of the dissociation constant of each enzyme for the ds-DNA<sup>met</sup> ligand ( $K_{DNA}$ ), indicated by a red arrow in each panel.


Fig. S4

```

                                15                                37
                                ▼                                ▼
MTB  -----MIHYRTIDSPIGPLTLAGHGSVLTNLRMLEQTY-----EPSRTHWTPDPGAFS
SULFO -----MIVYGLYKSPFGPITVAKNEKGFVMLDFCDCAE-----RSS-----LDNDYFD
ECOLI MTAKQFRHGGENLAVRYALADCELGRCLVAESERGICAILLGDDDATLISELQOMFPAADNAPADLMFQ
PYRO  -----MLSVEKFRVGERVVWIGVIFSGRVQGI AFADRGTLMKRIHDLAEHLGKRGVSI SLDV
METJ  -----MIIQIEEYFIGMIFKGNQLVRNTIPLRREEIFNFMDG-----EVVSNPED
HUM   -----MDKDCEMKRTTLDSPGLKLELSGCEQGLHEIKLLGKGTS-AADAVEVPAPAAVLGGPEPLM
                                :           .           :


```

B.



**Structural comparison of *Mt*OGT with OGTs from different species - A.** The figure shows the primary ClustalW-generated sequence alignment of equivalent moieties of the N-terminal domains of OGTs whose structures have been deposited with the protein data bank. **MTB**: *Mycobacterium tuberculosis*; **SULFO**: *Sulfolobus tokodaii*; **ECOLI**: *Escherichia coli*; **PYRO**: *Pyrococcus kodakaraensis*; **METJ**: *Methanococcus jannaschii*; **HUM**: human AGT. The random-coiled region in *M. tuberculosis* OGT is highlighted in green and residues belonging to the h1 helical turn are boxed. The red arrowheads label the residues mutated in *Mt*OGT-T15S and *Mt*OGT-R37L, respectively. Residues rendered in red in the human sequence are not visible in the human AGT structures. **B.** Cartoons of the indicated structures after optimal superposition to the *Mt*OGT model; each panel shows only the N-terminal domain (depicted in green in *Mt*OGT and in black in all other structures) and part of the inter-domain connecting loop (invariably colored in magenta).

Fig. S5



**Crystal packing of *MtOGT*** - Close up view of the interacting regions of the C-terminal domain of one chain (gray) and the tail of its symmetry mate (yellow, residues labeled by an asterisk) as observed in the *MtOGT* crystal lattice (upper image); only the residues involved in the closest interactions are labeled and shown as sticks; bond distances (Å) are indicated as dotted lines.